Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 1223 more sites in the U.S.
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Locations: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
+ 378 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Locations: - Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
+ 259 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…
Sponsor: AstraZeneca
NCT ID: NCT05774951
Locations: - Research Site — Birmingham, Alabama
- Research Site — Dothan, Alabama
- Research Site — Anchorage, Alaska
+ 124 more sites in the U.S.
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Locations: - Infirmary Cancer Care ( Site 0001) — Mobile, Alabama
- Ironwood Cancer & Research Centers-Research ( Site 0054) — Chandler, Arizona
- MemorialCare Orange Coast Medical Center ( Site 9501) — Fountain Valley, California
+ 89 more sites in the U.S.
Phase 3 Recruiting Industry
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…
Sponsor: AstraZeneca
NCT ID: NCT06380751
Locations: - Research Site — Gilbert, Arizona
- Research Site — Fountain Valley, California
- Research Site — Glendale, California
+ 57 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Locations: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- UC San Diego Health System - Encinitas — Encinitas, California
+ 55 more sites in the U.S.
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Beverly Hills Cancer Center — Beverly Hills, California
- City of Hope National Medical Center — Duarte, California
+ 49 more sites in the U.S.
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Locations: - Clinical Trial Site — Hot Springs, Arkansas
- Clinical Trial Site — Beverly Hills, California
- Clinical Trial Site — La Jolla, California
+ 44 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Locations: - Local Institution - 0303 — Hot Springs, Arkansas
- Helios Clinical Research — Cerritos, California
- Local Institution - 0307 — Cerritos, California
+ 43 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Locations: - Ironwood Cancer & Research Centers ( Site 0066) — Chandler, Arizona
- Banner MD Anderson Cancer Center-Oncology ( Site 0004) — Gilbert, Arizona
- Providence Medical Foundation-Oncology ( Site 0020) — Fullerton, California
+ 43 more sites in the U.S.
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (H…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07060807
Locations: - Southern Cancer Center (SCC) ( Site 8000) — Daphne, Alabama
- The University of Arizona Cancer Center - North Campus ( Site 0055) — Tucson, Arizona
- Los Angeles Hematology Oncology Medical Group ( Site 0026) — Los Angeles, California
+ 31 more sites in the U.S.